SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023
– In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® –
Related news for (SIGA)
- Calidi Biotherapeutics Advancing RTNova in Collaboration with SIGA Technologies
- SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
- SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results
- SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox